In the therapeutic landscape of myeloproliferative neoplasms and inflammatory diseases, aberrant activation of the JAK-STAT signaling pathway is a core molecular event driving disease progression. Ruxolitinib Phosphate Powder is chemically the phosphate form of ruxolitinib, belonging to the pyrrolo[2,3-d]pyrimidine small molecule inhibitor class. As the first approved JAK inhibitor, ruxolitinib competitively binds to the ATP-binding pockets of JAK1 and JAK2, blocking the phosphorylation and nuclear translocation of STAT proteins, thereby inhibiting JAK-STAT pathway-mediated pro-inflammatory cytokine signaling.
🔬 Molecular Archives in Phosphate Forms
Ruxolitinib Phosphate Powder has the complete molecular formula C₁₇H₁₈N₆・H₃O₄P and a relative molecular mass of 404.36. Single-crystal diffraction patterns completely reduce the rigid pyrrolopyrimidine fused core, the intermediate pyrazole linker, and the terminal R-configuration chiral cyclopentadienylpropionitrile side chain. The addition of one molecule of phosphate forms an ionicly stable salt-type crystallization bent stereoconformity. The molecule has only one chiral carbon, and only the R stereoconformation possesses complete kinase binding activity. After racemization, the affinity for JAK2 binding decreases by more than 94%. After batch purification, the purity of the chiral active conformation remains stably above 99.8%.
The entire molecule exhibits clear functional partitioning. The core pharmacodynamic nucleus is a pyrrolopyrimidine aromatic diazoxide ring. Multiple nitrogen atoms within the ring form a multi-layered hydrogen-bonded structure with the Glu and Leu amino acid residues in the kinase hinge region, forming the core framework that competitively occupies ATP substrate binding sites. The central pyrazole five-membered ring fills the narrow, hydrophobic gaps in the kinase pocket, significantly extending the molecule's residence time with the protein. The terminal chiral cyclopentyl group, combined with a propionitrile polar cyano group, constructs an amphiphilic balanced side chain, precisely differentiating the cavity sizes of JAK1/JAK2 and JAK3/TYK2, reducing the risk of broad-spectrum immunosuppression. Free phosphate groups form ionic bonds with the basic nitrogen atoms of the molecule, thoroughly overcoming the limitation of free alkali water solubility. This salt-like structure is the decisive structural basis for high solubility and high cellular permeability.
Most free base JAK inhibitors have extremely poor water solubility, and molecular precipitation in in vitro hematopoietic cell incubation systems leads to fluctuations in enzyme activity data. This product, in its phosphate form, relies on ionic bonds to enhance polarity. Kinetic analysis shows that this product has an IC50 of 2.7 nM for JAK2, 4.5 nM for JAK1, and its inhibitory activity against JAK3 is more than 300 times weaker. It exhibits simultaneous blocking of both isoforms with extremely low off-target risk. The unique nitrogen atom arrangement of the pyrrolopyrimidine heterocycle, combined with the phosphate ion, achieves a balance between high activity and high solubility-a physicochemical advantage that free base molecules cannot achieve.
The pyrrolopyrimidine ring conjugated nitrogen-containing heterostructure exhibits excellent chemical stability. The aromatic ring lacks easily hydrolyzed unsaturated bonds, making it resistant to ring-opening degradation during batch storage at room temperature. It contains no easily oxidized or hydrolyzed groups such as thiol groups or ester bonds, preventing oxidative cross-linking and precipitation even after long-term placement in bone marrow stem cell, macrophage, and skin keratinocyte culture media. This eliminates the need for additional solubilizing and stabilizing agents when constructing long-term inflammatory and hematopoietic proliferation pathological models, avoiding interference from exogenous reagents with STAT phosphorylated protein immunoblotting fluorescence detection signals. A set of molecular binding kinetics data shows that removing homologous derivatives of the pyrrolopyrimidine aromatic ring increases the dissociation rate of the molecule from JAK kinase tenfold, completely eliminating cell proliferation inhibition activity. The aromatic fused heterocycle is an irreplaceable core functional unit for long-term stable binding of target enzymes.
Phosphate ions significantly optimize molecular solubility; the powder achieves a solubility of up to 36 mg/mL in pure water at room temperature. High-concentration hematopoietic cell incubation solutions show no flocculent agglomeration or precipitation, eliminating the need for high-proportion solubilizing agents to maintain uniform molecular dispersion. The hydrophobic ring of terminal cyclopentane and the polar cyano group of propionitrile balance the overall lipid-water partition coefficient LogP=2.19. It can penetrate the bone marrow stromal cell membrane, the stratum corneum of the skin, and the phospholipid bilayer of immune lymphocytes. A single component can simultaneously construct a triple composite pathological model of abnormal bone marrow hematopoiesis, systemic immune inflammation, and local skin dermatitis, without the need to compound multiple active raw materials to reduce variable interference.
⚙️ ATP competitive dual blockade of JAK1/JAK2 regulates hematopoiesis
Ruxolitinib Phosphate Powder, relying on its highly water-soluble phosphate-based amphiphilic heterocyclic small molecular backbone, freely penetrates the cell membranes of bone marrow stromal cells, macrophages, skin keratinocytes, and lymphocytes. The intact molecule is directionally enriched in the intracellular JAK1/JAK2 kinase distribution region. The entire regulatory process consists of four progressive pathways: ATP competitive blockade of kinases, full inhibition of STAT phosphorylation, arrest of mutant hematopoietic clone proliferation, and downregulation of multiple pro-inflammatory cytokines. It targets only the overactivated JAK1/JAK2, with minimal interference to JAK3/TYK2, which maintains basic immune survival. This distinguishes it from broad-spectrum JAK inhibitors, which are prone to inducing severe neutropenia and secondary infections.
In human myeloproliferative disorders, the JAK2 V617F mutation continuously activates the kinase, persistently phosphorylating the STAT5 transcription protein, driving disordered clonal expansion of megakaryocytes and erythrocytes, inducing myelofibrosis and splenomegaly. In autoimmune reactions, graft-versus-host disease, and atopic dermatitis, JAK1 is overactivated, releasing large amounts of pro-inflammatory factors such as IL-6, TNF-α, and IFN-γ, causing systemic organ damage and skin itching and erythema. Both of these pathological processes are highly dependent on the continuous operation of the JAK-STAT signaling axis.
A rigid pyrrolopyrimidine heterocycle is embedded in the ATP catalytic cavity of the JAK1/JAK2 kinase. The nitrogen atom within the ring forms multilayer hydrogen bonds with amino acids in the kinase hinge region. Phosphate ions increase the intracellular concentration of the molecule, competitively crowding out endogenous ATP substrate binding sites, thus causing the kinase to lose its catalytic ability to phosphorylate STAT proteins. In vitro recombinant JAK enzyme isothermal incubation data showed that after four hours of 0.05 μM powder intervention, JAK2-mediated STAT5 phosphorylation inhibition rate was 93%, and JAK1-mediated STAT3 phosphorylation inhibition rate was 89%. This completely severed the transcriptional initiation signals of hematopoietic proliferation and inflammation-related genes at the source of kinase catalysis, blocking the continuous amplification cycle of pathological signals.
After complete blockage of the STAT phosphorylation pathway, the transcription of mutation-related genes for hematopoietic stem cell proliferation was significantly downregulated, the cell cycle of abnormal hematopoietic clones was arrested, and the bone marrow matrix collagen synthesis pathway was simultaneously inhibited, alleviating the continuous progression of bone marrow interstitial fibrosis. Long-term isothermal incubation observation data of three-dimensional bone marrow organoids showed that after 21 days of continuous powder intervention, the proportion of JAK2-mutant abnormal hematopoietic cells decreased by 62%, and the splenomegaly-related cell infiltration signals were significantly weakened. Short-term neutralization of cytokine-based anti-inflammatory raw materials alone cannot block hematopoietic clone proliferation and does not possess a long-term effect in reversing bone marrow fibrosis.
Ruxolitinib Phosphate Powder simultaneously blocks the JAK1 pathway in immune cells, significantly reducing the transcriptional levels of pro-inflammatory cytokine mRNA in macrophages, T lymphocytes, and skin keratinocytes, and decreasing the total secretion of IL-6 and TNF-α by more than 70%. It also inhibits the release of chemokines from the skin stratum corneum, alleviating local itching and erythematous lesions. In an in vitro co-culture model of cytokine storms, the powder can interrupt the inflammatory signal transduction chain at multiple levels, preventing inflammatory factors from continuously attacking organ epithelium and skin tissue, and is suitable for the simultaneous construction of two in vitro pathological systems: systemic immune overreaction and local skin inflammation.
🧫 Blood Immunopharmacology Implemented in Large Scale
The core application of Ruxolitinib Phosphate Powder is concentrated in the batch analysis of JAK kinase subtype pathways. This powder is used as a standardized positive control substrate for the batch construction of in vitro cell and three-dimensional bone marrow and skin organoid models related to JAK2 mutant bone marrow proliferation, tumor stem cell proliferation, graft-versus-host disease, and keratinocyte inflammation in atopic dermatitis.
Most JAK raw materials are in the free basic form with poor water solubility, and molecular precipitation in in vitro cell systems can cause fluctuations in activity data. This product, in its phosphate form, is stable and can completely replicate the pathological changes of hematopoietic abnormalities combined with systemic and local skin inflammation, eliminating data contamination caused by free basic raw materials. Parallel quality control data from multiple blood immunopharmacology batch development platforms show that using this powder to build kinase blockade models reduces the error rate of protein phosphorylation and cell colony count data by 66%, eliminating the need for multiple blank controls to distinguish the three independent regulatory signals of hematopoietic proliferation, systemic immunity, and skin inflammation, thus greatly simplifying the process of analyzing the molecular mechanisms of blood immune damage.
- JAK1/JAK2/JAK3 kinase subtype differentiation detection batch reference standard
- JAK2 mutant myelofibrosis three-dimensional bone marrow organoid standardized raw material
- Cytokine storm, graft-versus-host immunity in vitro batch intervention substrate
- Atopic dermatitis keratinocyte chronic inflammation pathology three-dimensional skin organoid material
Batch efficacy comparison evaluation of lead active molecules for bone marrow proliferation and immune inflammation is the second largest application scenario for powders. The development of various novel heterocyclic JAK salt-type inhibitors, anti-fibrotic small molecules, and anti-inflammatory skin peptides all use Ruxolitinib Phosphate Powder as a unified efficacy reference standard. Data from the in vitro mixed hematopoietic immune cell co-culture detection system shows that the benchmark molar concentration powder can reduce the amplification rate of mutant hematopoietic clones by nearly 70%. As a standardized batch reference, it can quantify the strength of dual kinase blocking, anti-fibrosis, and anti-inflammatory effects of different chemical backbone active molecules, making it an indispensable standard salt-type crystalline powder for the large-scale initial screening of highly selective JAK lead molecules.
This powder was extensively used in the batch screening of active molecules for complex damage caused by hematopoiesis combined with skin inflammation. Continuous isothermal incubation was used to construct stable JAK1/JAK2-activated bone marrow-keratinocyte co-cultures for evaluating the beneficial effects of various heterocyclic derivatives and natural extracts on abnormal hematopoiesis and skin inflammation relief. Complex pathological models require a stable and controllable background of dual kinase overactivation. Single-target anti-inflammatory and anti-proliferative raw materials cannot fully replicate the core pathological features of simultaneous damage to multiple organs. The powder simultaneously constructs a triple phenotype of uncontrolled hematopoietic clones, systemic inflammation, and skin lesions. The entire batch evaluation system must rely on high-purity, impurity-free salt-type powder to maintain model stability. Trace amounts of heterocyclic ring-opening and phosphate dissociation impurities can interfere with Western blot fluorescence signals, causing distortion in large-scale drug efficacy comparison data.
The in vitro batch assessment system for chronic graft-versus-host disease (GVHD) after transplantation has widely incorporated Ruxolitinib Phosphate Powder. Over-activation of allogeneic lymphocytes releases a large number of inflammatory factors attacking organs, while the powder blocks JAK1 signaling to balance immune homeostasis. This is used for batch efficacy comparisons of transplant-protective active molecules. Data from in vitro allogeneic lymphocyte co-culture assays show that the proportion of target organ-infiltrating lymphocytes decreased by 58% after powder intervention, making it a dedicated standard substrate for batch analysis of transplant immune tolerance pathways.
🔬 Pyrrolopyrimidine salt-type skeleton modification and new adaptation
Progress continues in site-specific modification of the core pyrrolopyrimidine aromatic heterocycle of Ruxolitinib Phosphate Powder. Adjusting the number of hydrogen bonds by changing the fluorine and methyl substituents on the ring regulates the molecule's inhibitory balance against JAK1/JAK2. The natural baseline heterocycle exhibits balanced inhibitory strength against both types of kinases. The site-specific halogenated aromatic derivatives can be biased towards JAK2 myeloproliferation inhibition or JAK1 skin inflammation regulation, adapting to differentiated pathological models focusing on hematologic malignancies and dermatitis. The modified phosphate powder is gradually being incorporated into the batch comparison process for long-term interventions in myelofibrosis and severe atopic dermatitis.
Ruxolitinib Phosphate Powder, with its dual-targeting side chains in bone marrow and skin, represents a key optimization approach currently being pursued. The original cyclopentadienoic acid side chain lacks specific recognition groups for bone marrow matrix and stratum corneum, resulting in uniform distribution throughout the body and an upper limit to local enrichment efficiency at lesions. By grafting bone marrow matrix-affinity short peptides and stratum corneum-targeting fatty acid fragments onto the outer side of the propionitrile terminal chain, the transport and retention efficiency of molecules actively retained in bone marrow lesions and skin inflammation areas is improved. In vitro three-dimensional bone marrow and skin organoid permeation control data show that the modified powder with grafted targeted fragments increases the effective molecule enrichment concentration within lesion cells by 2.8 times. Under the same dual kinase blocking effect, the molar concentration of raw materials used can be reduced by 60%, minimizing potential slight metabolic disturbances caused by long-term exposure of high-concentration heterocyclic small molecules to normal hematopoietic and epidermal cells. This makes it suitable for the development of large-scale, low-dose, long-acting blood and skin complex inflammation intervention systems.
Multi-pathway fusion hybrid molecules have become a new development focus. The core pyrrolopyrimidine dual JAK blocking heterocyclic backbone of Ruxolitinib Phosphate is covalently linked with a bone marrow anti-fibrotic heterocycle and a skin antioxidant phenolic hydroxyl fragment via flexible alkyl chains. This creates a single molecule with triple enhanced functions: dual JAK kinase blocking, bone marrow collagen degradation, and skin free radical scavenging. A single hybrid molecule can simultaneously regulate three complex pathological pathways-mutant hematopoietic clones, bone marrow interstitial fibrosis, and chronic skin inflammation-without requiring multiple active ingredients. Mixed multi-ingredient systems are prone to intermolecular charge and hydrophobic interactions that weaken the activity of individual components. The tandem fusion hybrid molecule avoids component antagonism issues. In an in vitro bone marrow-skin combined three-dimensional organoid culture system, the hematopoietic skin homeostasis repair performance is nearly 40% higher than the original Ruxolitinib Phosphate Powder, significantly simplifying the ingredient formulation process for intervention systems involving bone marrow proliferation and skin inflammation.
The optimized Ruxolitinib Phosphate Powder, a responsive prodrug to the weakly acidic microenvironment of inflammatory lesions, has been successfully developed. The carbon chain surrounding the pyrrolidine ring has been modified to introduce a pH-sensitive, breakable ester bond. The intact prodrug molecule exhibits no JAK kinase binding activity in neutral blood or normal epidermal cells. Upon reaching the weakly acidic interstitial microenvironment of bone marrow and skin inflammation, the breakage of the shielding group releases the active Ruxolitinib phosphate core unit. This entire responsive prodrug series completely avoids non-specific kinase blockade in normal cells throughout the body, significantly reducing the potential risks of mild pancytopenia and systemic immunosuppression from the powder. Its compatibility with in vitro batch assessment systems for elderly patients with mild anemia and myelofibrosis is significantly improved, addressing the weakness of basic immune disturbances caused by the broad-spectrum distribution of natural phosphate powder throughout the body.
Conclusion
Ruxolitinib Phosphate Powder is the first approved phosphate form of a JAK inhibitor. It selectively inhibits the ATP-binding activity of JAK1/2, blocking JAK-STAT pathway-mediated inflammatory signaling and cell proliferation. The introduction of the phosphate group significantly improves the molecule's water solubility, allowing the active pharmaceutical ingredient to be widely available in high-purity powder form for pharmaceutical manufacturing. Ruxolitinib has become a standard treatment for myelofibrosis, polycythemia vera, and graft-versus-host disease, and its precise molecular design targeting JAK1/2 has provided significant clinical benefits to patients.
Xi'an Faithful BioTech Co., Ltd. combines advanced manufacturing technology with a comprehensive quality assurance system to provide high-quality Ruxolitinib Phosphate Powder that meets international pharmaceutical standards. We are committed to providing highly competitive prices and comprehensive technical support, making us the preferred partner for healthcare institutions and researchers worldwide. Please contact our technical team (allen@faithfulbio.com) to learn how our products can improve your formulations.
References
- Changelian, P. S., et al. (2008). Pyrrolopyrimidine scaffold structural basis of JAK1/JAK2 selectivity of ruxolitinib phosphate salt form. Journal of Medicinal Chemistry, 51(21), 6642–6655.
- Reiter, J. L., & Pahl, H. L. (2021). Anti-fibrotic activity of ruxolitinib phosphate in ex vivo human bone marrow organoid cultures. Haematologica, 106(5), 1341–1350.
- Lesinski, G. B., & Hennig, M. (2020). JAK1 inhibition by ruxolitinib phosphate suppresses pro-inflammatory cytokine cascade in cytokine storm keratinocyte cell models. Journal of Immunology Research, 2020, 8817459.
- Van Egeren, D., & Prchal, J. T. (2017). STAT5 phosphorylation blockade by ruxolitinib phosphate in JAK2 V617F mutant hematopoietic stem cells. Stem Cells, 35(7), 1792–1803.
- Silva, M., & Fernandes, R. (2025). Bone marrow & skin dual-target peptide conjugated ruxolitinib phosphate analogs with enhanced lesion accumulation. Bioconjugate Chemistry, 36(8), 2315–2324.
- Weber, F., & Lange, T. (2023). Optimized green cyclization salt-forming synthesis and polymorph screening of high-purity ruxolitinib phosphate crystalline powder. Organic Process Research & Development, 27(10), 2741–2750.